Phenotypes associated with this allele

• Allele Symbol: Dsc2^tm1.2Leu
• Allele Name: targeted mutation 1.2, Rudolf E Leube
• Allele ID: MGI:6509042
• Summary: 1 genotype

Jump to	Allelic Composition	Genetic Background	Genotype ID
hm1	Dsc2^tm1.2Leu/Dsc2^tm1.2Leu	involves: C57BL/6	MGI:6693493

Genotype
MGI:6693493

hm1

• Allelic Composition: Dsc2^tm1.2Leu/Dsc2^tm1.2Leu
• Genetic Background: involves: C57BL/6

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

cardiovascular system

cardiovascular system phenotype ( J:302593 )

N • normal myocardium, epicardium, trabecular layers, cardiac septum and vascularization in E13.5 embryo hearts

N • normal adult heart morphology (e.g. ventricular size and wall thickness, ventricular septum thickness) and function (e.g. ejection fraction (EF) and fractional shortening (FS)): no fibrosis or inflammation

N • normal myocardial desmosomes and adherens junctions

N • normal myocardial sarcomeres and intermediate filaments

N • normal left ventricular wall and ventricular septum thickness, left ventricle size and cardiac hypertrophy after 14 days angiotensin II administration

cardiac hypertrophy ( J:302593 )

• hypertrophic left and right ventricle cardiomyocytes after 14 days angiotensin II administration after trans-aortic constriction (TAC)

heart left ventricle hypertrophy ( J:302593 )

• after trans-aortic constriction (TAC)

cardiac fibrosis ( J:302593 )

• after 14 days angiotensin II administration and after trans-aortic constriction (TAC)

decreased heart left ventricle muscle contractility ( J:302593 )

• reduced left ventricle ejection fraction (EF) and fractional shortening (FS) after 14 days angiotensin II administration and after trans-aortic constriction (TAC)

muscle

heart left ventricle hypertrophy ( J:302593 )

• after trans-aortic constriction (TAC)

decreased heart left ventricle muscle contractility ( J:302593 )

• reduced left ventricle ejection fraction (EF) and fractional shortening (FS) after 14 days angiotensin II administration and after trans-aortic constriction (TAC)

embryo

embryo phenotype ( J:302593 )

N • born at expected Mendelian ratio

N • no gross abnormalities at stage E13.5: no pigmentation or hematological abnormalities

N • normal myocardium, epicardium, trabecular layers, cardiac septum and vascularization in E13.5 embryo hearts

growth/size/body

growth/size/body region phenotype ( J:302593 )

N • normal size; no gross abnormalities

N • normal skin, fur, mucous epithelium and whiskers

N • normal heart, epidermis, lung, kidney, intestine, liver and spleen histology

cardiac hypertrophy ( J:302593 )

• hypertrophic left and right ventricle cardiomyocytes after 14 days angiotensin II administration after trans-aortic constriction (TAC)

heart left ventricle hypertrophy ( J:302593 )

• after trans-aortic constriction (TAC)

mortality/aging

mortality/aging ( J:302593 )

N • viable

cellular

increased apoptosis ( J:302593 )

• in heart after 14 days angiotensin II administration

reproductive system

reproductive system phenotype ( J:302593 )

N • fertile